CiVentiChem Appoints Glenn Killingworth to Director

Online, September 27, 2010 (Newswire.com) - CiVentiChem
Appoints Glenn Killingworth to Drive Business Development into New
R&D and Pilot Plant Investments in North Carolina

Supporting recent investments at both their US headquarters in North
Carolina and their pilot and production facility in Hyderabad, India,
CiVentiChem has appointed Glenn Killingworth as Director of Business
Development as part of the company's overall growth strategy. Glenn's
vast experience in the field will benefit the launch of their new assets
in Hyderabad, India and cGMP kilo-lab synthesis capabilities in Cary,
North Carolina.

Glenn brings over 20 years experience of sales, marketing, collaborative
ventures and business development in both Europe and the US, along with
a strong scientific background in the field of pharmaceutical and
chemistry research and development.

He joins CiVentiChem from his most recent position as Director of Key
Accounts at WiXi AppTec where he was responsible for the development of
European-centric global pharmaceutical companies. Previously, Glenn held
a post on the Operational Board at Peakdale Molecular. During his role
at Almac Sciences, in Northern Ireland, he worked with both European and
US-based companies. Previously he was Business Development Manager at
Fisher Scientific UK, where he successfully introduced Fisher
Scientifics' custom synthesis business in the US marketplace.

"Glenn has built a proven track record of commercial success through
sales development, strategic marketing and novel collaborative
ventures," said Bhaskar Venepalli, President of CiVentiChem. "We are
delighted to have Glenn on board at a very critical juncture of our
growth plans and our drive to expand our market share with the
investments we recently made in North Carolina as well as in Hyderabad,
India" said Venepalli.

"I am delighted to join CiVentiChem's management team at an exciting
time in the company's expansion," added Glenn. "The multinational
business model of US Headquarters and R&D and development
capabilities in the US and India offers a compelling solution to
pharmaceutical clients. I admire the enthusiasm and teamwork, enabling
innovative approaches to solving complex chemistry problems," said
Killingworth.

About CiVentiChem: Headquartered in the regional research and
development stronghold of North Carolina's Research Triangle,
CiVentiChem, through its core competence of complex organic chemistry,
has forged a successful business providing pharmaceutical, biotechnology
and agrochemical companies with contract research, custom synthesis,
process development and contract manufacturing services. The company was
founded by Bhaskar Venepalli and Duke University scientist Srinivas
Chittineni in 1994 and now employs 65 people.